Producing recombinant SARS-CoV-2 spike protein in a pre-fusion state
Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells). The pre-fusion state SARS-CoV-2 spike protein can be used as an antigen to generate antibodies/binding molecules for use in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; as a therapeutic to interfere with SARS-CoV-2 cellular binding; to generate antibodies/binding molecules to SARS-CoV-2 for use in therapy; or, as a vaccine for generating immunity to SARS-CoV-2; or for prophylactic or therapeutic use against related coronaviruses.
C C C C C C C A C C A A C C C
C12N C12N C12N C07K C07K C12Y C12N A61K C12N C07K A61K A61P C12N C07K C07K
additional inventional additional inventional additional inventional additional inventional additional additional inventional inventional inventional additional inventional
Jun Yang
Li Xiang